NEW ANTIPLATELET DRUGS (PART 1)
Рациональная фармакотерапия в кардиологии, 2016 Antiplatelet agents are a necessary component of modern atherosclerosis therapy. The difficulties of antiplatelet treatment lie in the balance between the necessary therapeutic effect of the drug and the risk of excessive action leading to the bleeding ...
A. B. Sumarokov
doaj +3 more sources
DENTAL MANAGEMENT AND BLEEDING COMPLICATIONS OF PATIENTS ON LONG-TERM ORAL ANTIPLATELET THERAPY. REVIEW OF EXISTING STUDIES AND GUIDELINES. [PDF]
Journal of IMAB, 2013 Antiplatelet drugs are currently widely used in primary and especially secondary prevention of cardiovascular events. Dental management of patients on antiplatelet therapy is still not clearly defined: the discontinuation of antiplatelet therapy ...
Atanaska Dinkova +2 more
doaj +1 more source
Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation. [PDF]
, 2020 Importance: Patients with nonvalvular atrial fibrillation at risk of stroke should receive oral anticoagulants (OAC). However, approximately 1 in 8 patients in the Global Anticoagulant Registry in the Field (GARFIELD-AF) registry are treated with ...
Bassand, J-P +17 more
core +2 more sources
Pharmacogenomics of antiplatelet drugs [PDF]
Hematology, 2014 Abstract Clopidogrel, a platelet P2Y12 inhibitor, is one of the most widely prescribed drugs in cardiovascular medicine because it reduces ischemic and thrombotic complications. It is a prodrug requiring biotransformation into the active metabolite by the hepatic cytochrome 450 system, especially the CYP2C19 enzyme.
Marc S, Sabatine, Jessica L, Mega
openaire +2 more sources
Research progress of antithrombotic drugs [PDF]
Jichu yixue yu linchuang, 2023 Thrombosis is the main direct cause of acute manifestations of atherosclerotic cardiovascular disease (myocardial infarction, stroke). Globally, the incidence of thromboembolic diseases has increased in recent years, accompanied by an increase in patient
ZHANG Jie, MA Xuzhou, LI Huihui, WANG Miao
doaj +1 more source
Coming safely to a stop : a review of platelet activity after cessation of antiplatelet drugs [PDF]
, 2015 Funding Isobel Ford is an employee of the University of Aberdeen. The research for the writing of this review received no specific grant from any funding agency in the public, commercial, or not-forprofit sectorsPeer ...
Ford, Isobel
core +1 more source
Adherence to secondary stroke prevention strategies - Results from the German stroke data bank [PDF]
, 2003 Only very limited data are available concerning patient adherence to antithrombotic medication intended to prevent a recurrent stroke. Reduced adherence and compliance could significantly influence the effects of any stroke prevention strategies.
Busse, O. +4 more
core +1 more source
Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study. [PDF]
, 2014 ObjectiveThere is insufficient evidence on which to base a recommendation for optimal antiplatelet therapy following a stroke while on aspirin. The objective was to compare clopidogrel initiation vs aspirin reinitiation for vascular risk reduction among ...
Chang, Ku-Chou +10 more
core +1 more source
Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications [PDF]
, 2018 © The Author(s) 2018The stability of an arterial thrombus, determined by its structure and ability to resist endogenous fibrinolysis, is a major determinant of the extent of infarction that results from coronary or cerebrovascular thrombosis.
A Gast +66 more
core +2 more sources
Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial [PDF]
, 2019 Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage.
Al-Shahi Salman, Rustam +16 more
core +1 more source